论文部分内容阅读
对伴门静脉癌栓形成的原发性肝癌患者，行肝动脉化学栓塞加转铁蛋白受体单克隆抗体（ＴＦＲ－Ｍ）生物导向治疗，并与单纯肝动脉化学栓塞作对照比较。结果显示，观察组瘤体缩小＞５０％的部分缓解率为５８．３％（１４／２４），门静脉癌栓消失、缩小的有效率为８３．３％（２０／２４），均显著优于对照组的１８．２％（４／２２）和２７．３％（６／２２），差异有高度显著性（Ｐ＜０．０５～０．０１）。观察组所有应用ＴＦＲ－Ｍ治疗的病例均未发生任何血清病样过敏反应。观察表明，伴门静脉癌栓晚期原发性肝癌序贯栓塞化疗结合生物导向治疗可取得较好疗效。
Liver cancer patients with portal vein tumor thrombus were treated with hepatic artery embolization plus transferrin receptor monoclonal antibody (TFR-M) bioguided treatment and compared with simple hepatic artery chemical embolization. The results showed that the partial remission rate was >50% (14/24) in the observation group, and the effective rate of disappearance and reduction of portal vein tumor emboli was 83.3% (20/24). In the control group, 18.2% (4/22) and 27.3% (6/22) were highly significant (P<0.05-0.01). No serum-like allergic reaction occurred in all patients treated with TFR-M in the observation group. Observations showed that sequential embolization chemotherapy combined with bioguided treatment of portal vein cancer thrombus with advanced primary hepatocellular carcinoma can achieve better results.